MX362382B - Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. - Google Patents

Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Info

Publication number
MX362382B
MX362382B MX2016005314A MX2016005314A MX362382B MX 362382 B MX362382 B MX 362382B MX 2016005314 A MX2016005314 A MX 2016005314A MX 2016005314 A MX2016005314 A MX 2016005314A MX 362382 B MX362382 B MX 362382B
Authority
MX
Mexico
Prior art keywords
adamts13
stabilized liquid
adamts13 formulations
lyophilized adamts13
lyophilized
Prior art date
Application number
MX2016005314A
Other languages
English (en)
Spanish (es)
Inventor
Schwarz Hans-Peter
Peter Matthiessen H
L Turecek Peter
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX362382B publication Critical patent/MX362382B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
MX2016005314A 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. MX362382B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24435309P 2009-09-21 2009-09-21
PCT/US2010/049723 WO2011035335A2 (en) 2009-09-21 2010-09-21 Stabilized liquid and lyophilized adamts13 formulations

Publications (1)

Publication Number Publication Date
MX362382B true MX362382B (es) 2019-01-14

Family

ID=43598388

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016005314A MX362382B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2012003414A MX339205B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2019000547A MX2019000547A (es) 2009-09-21 2012-03-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2012003414A MX339205B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2019000547A MX2019000547A (es) 2009-09-21 2012-03-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Country Status (21)

Country Link
US (9) US8623352B2 (en:Method)
EP (5) EP4218797B9 (en:Method)
JP (2) JP5819303B2 (en:Method)
KR (6) KR20210054598A (en:Method)
CN (2) CN104224705B (en:Method)
AU (1) AU2010295299B2 (en:Method)
BR (1) BR112012006283B1 (en:Method)
CA (1) CA2774556A1 (en:Method)
DK (4) DK4218797T5 (en:Method)
EA (1) EA024267B1 (en:Method)
ES (4) ES2948612T3 (en:Method)
FI (2) FI3834841T3 (en:Method)
FR (1) FR24C1049I1 (en:Method)
HR (1) HRP20160295T1 (en:Method)
HU (1) HUE028688T2 (en:Method)
IN (1) IN2012DN02645A (en:Method)
MX (3) MX362382B (en:Method)
NZ (1) NZ598839A (en:Method)
PL (4) PL3167897T3 (en:Method)
PT (2) PT4218797T (en:Method)
WO (1) WO2011035335A2 (en:Method)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745805C (en) 2008-12-05 2021-01-19 Baxter International Inc. Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
DK4218797T5 (da) 2009-09-21 2025-07-21 Takeda Pharmaceuticals Co Stabiliseret væske og frysetørrede adamts13-formuleringer
EP3311847A1 (en) * 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
CN103566362B (zh) * 2012-07-21 2015-07-29 复旦大学 重组adamts13在制备脑出血药物中的用途
CA2890848C (en) 2012-11-09 2020-11-17 Puget Sound Blood Center Protein stabilizing factors apolipoprotein a-1 or high density lipoprotein
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
CA2952609A1 (en) * 2014-06-26 2015-12-30 Amgen Inc. Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
EP3401685B1 (en) * 2016-01-08 2021-12-01 Kyoto University Diagnostic method and medicine comprising adamts13 as main ingredient
AU2017307582C1 (en) * 2016-08-04 2021-05-06 Takeda Pharmaceutical Company Limited Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
BR112019009113A2 (pt) 2016-11-04 2019-07-16 Baxalta GmbH formulações de vírus adenoassociado
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
TWI810196B (zh) * 2017-07-25 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種il-15蛋白質複合物醫藥組成物及其用途
JP2021532071A (ja) * 2018-07-11 2021-11-25 バクスアルタ インコーポレイテッド Ａａｖ組成物
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
KR20230005192A (ko) 2020-04-02 2023-01-09 다케다 야쿠힌 고교 가부시키가이샤 Adamts13 변이체, 조성물 및 그의 용도
US20230201319A1 (en) 2020-05-22 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
US20230295597A1 (en) * 2020-08-13 2023-09-21 Hadasit Medical Research Services & Development Limited A disintegrin and metalloproteinase with a thrombospondin type i motif, member 13 (adamts-13) mutants, compositions and therapeutic methods thereof
EP4490042A1 (en) 2022-03-08 2025-01-15 Equashield Medical Ltd. Fluid transfer station in a robotic pharmaceutical preparation system
KR20240112755A (ko) * 2023-01-11 2024-07-19 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
ATE365052T1 (de) 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
JP2001227510A (ja) 2000-02-15 2001-08-24 Tomoe Tech Res Co 複作動型の空気式アクチュエータ
JP3783507B2 (ja) 2000-02-16 2006-06-07 日本精工株式会社 トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
ITPR20010055A1 (it) 2001-08-31 2003-03-03 Vetroarredo Spa Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko) 2002-10-09 2005-03-10 동부아남반도체 주식회사 모스 트랜지스터 제조 방법
WO2005008241A1 (en) * 2003-07-07 2005-01-27 University Of North Carolina At Chapel Hill Method and system for detection of von willebrand factor (vwf) multimers
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006133955A1 (en) 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
JP4880997B2 (ja) * 2005-12-28 2012-02-22 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の安定化方法
HUE032744T2 (en) 2006-01-04 2017-10-30 Baxalta Inc Oligopeptide-free cell culture medium
DK4218797T5 (da) * 2009-09-21 2025-07-21 Takeda Pharmaceuticals Co Stabiliseret væske og frysetørrede adamts13-formuleringer
US8823352B2 (en) 2011-07-11 2014-09-02 Linear Technology Corporation Switching power supply having separate AC and DC current sensing paths

Also Published As

Publication number Publication date
FI3834841T3 (fi) 2023-06-05
HRP20160295T1 (hr) 2016-05-20
PT4218797T (pt) 2024-12-09
DK3834841T3 (da) 2023-06-06
JP2015063556A (ja) 2015-04-09
JP2013505270A (ja) 2013-02-14
CA2774556A1 (en) 2011-03-24
DK4218797T3 (da) 2024-12-09
AU2010295299A1 (en) 2012-04-12
US10238720B2 (en) 2019-03-26
US10758599B2 (en) 2020-09-01
AU2010295299B2 (en) 2015-12-24
BR112012006283B1 (pt) 2022-03-15
US20200376098A1 (en) 2020-12-03
KR20180095738A (ko) 2018-08-27
US20170112906A1 (en) 2017-04-27
WO2011035335A2 (en) 2011-03-24
PL3834841T3 (pl) 2023-07-24
IN2012DN02645A (en:Method) 2015-09-11
EP3834841A1 (en) 2021-06-16
EP2480198B9 (en) 2016-11-23
DK4218797T5 (da) 2025-07-21
HK1173968A1 (zh) 2013-05-31
EP4218797A1 (en) 2023-08-02
US9351935B2 (en) 2016-05-31
KR20120099646A (ko) 2012-09-11
HUE028688T2 (en) 2017-01-30
EP3167897A1 (en) 2017-05-17
DK2480198T3 (en) 2016-03-29
US9937244B2 (en) 2018-04-10
US20140178357A1 (en) 2014-06-26
WO2011035335A3 (en) 2011-12-01
EP2480198A2 (en) 2012-08-01
US20180207245A1 (en) 2018-07-26
BR112012006283A2 (pt) 2016-05-31
US8623352B2 (en) 2014-01-07
ES2865250T3 (es) 2021-10-15
CN102573792B (zh) 2014-10-15
CN104224705A (zh) 2014-12-24
FR24C1049I1 (fr) 2025-01-17
KR20210054598A (ko) 2021-05-13
ES2948612T3 (es) 2023-09-14
EP2480198B1 (en) 2016-03-09
KR20190137954A (ko) 2019-12-11
EA024267B1 (ru) 2016-09-30
EP3167897B1 (en) 2021-01-27
KR20250008986A (ko) 2025-01-16
CN104224705B (zh) 2018-02-02
JP5819303B2 (ja) 2015-11-24
US11564979B2 (en) 2023-01-31
US12178861B2 (en) 2024-12-31
EP4218797B1 (en) 2024-09-11
US20190247475A1 (en) 2019-08-15
KR101891646B1 (ko) 2018-08-27
US20160375111A1 (en) 2016-12-29
DK3167897T3 (da) 2021-04-19
PL3167897T3 (pl) 2021-09-27
EP4467160A2 (en) 2024-11-27
MX2012003414A (es) 2012-06-19
PL2480198T3 (pl) 2016-09-30
US20110229455A1 (en) 2011-09-22
FI4218797T3 (fi) 2024-12-07
PL4218797T3 (pl) 2025-02-10
MX2019000547A (es) 2020-11-12
MX339205B (es) 2016-05-16
CN102573792A (zh) 2012-07-11
ES3001509T3 (en) 2025-03-05
EP4467160A3 (en) 2025-01-15
KR20220139456A (ko) 2022-10-14
ES2579906T3 (es) 2016-08-17
NZ598839A (en) 2014-03-28
US20250099559A1 (en) 2025-03-27
PT3834841T (pt) 2023-06-19
US9572778B2 (en) 2017-02-21
EP4218797B9 (en) 2025-04-30
US20230130866A1 (en) 2023-04-27
EA201200519A1 (ru) 2012-09-28
EP3834841B1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
MX362382B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
PE20230169A1 (es) Suministro al sistema nervioso central de agentes terapeuticos
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
AR071852A1 (es) Formulacion farmaceutica de un anticuerpo frente a ox40l
PE20121517A1 (es) Compuestos lipopeptidos y metodos relacionados
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20080658A1 (es) Formulaciones de metilnaltrexona en forma de polvo seco
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
SG179030A1 (en) Highly concentrated pharmaceutical formulations comprising anti - cd20 antibody
AR061289A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
PE20090064A1 (es) Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
ECSP088903A (es) Composiciones farmacéuticas de anticuerpo antagonista anti-cd40
ECSP088240A (es) Composición de trazodona para administración una vez por día
WO2010100200A3 (en) Lyophilised antibody formulation
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CL2011000848A1 (es) Composicion de crema topica estable que comprende ozenoxacina y un excipiente farmaceuticamente adecuado y uso de la composicion para la erradicacion de infecciones nasofaringeas en portadores nasales asintomaticos, y para el tratamiento o prevencion de infecciones de la piel, del tracto genital, y enfermedades de transmision sexual.
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
MX2010005013A (es) Composiciones intranasales.
BR112012021638A2 (pt) composição livre de conservantes estéril ótica farmacêutica na forma de uma solução aquosa clara.
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
RU2011122629A (ru) Водная композиция, содержащая фолликулостимулирующий гормон
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico